$SPRB

$43.99 -$1.16 (2.57%) Close

$SPRB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 2.9M shares outstanding

Who owns SPRB?

By type of holder

Institutions 69.8% Insiders 1.5% Everyone else 28.7%

Concentration Top 10 holders own 312.0%

Jay Schmelter 61.2% · John P. McKearn, Ph.D. 61.2%

Institutional ownership

69.8%

+44.1 pts vs last qtr

Institutional holders

+32 vs last qtr

Net shares bought

+1.3M

by institutions in Q2 2026

New / sold out

36 / 4

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

AIGH Capital Management LLC NEW +250.0K
Orbimed Advisors LLC NEW +200.0K

Biggest sellers in Q2 2026

Wellington Management Group LLP SOLD OUT −48.8K
Balyasny Asset Management L.P. −27.9K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Spruce Biosciences, Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2021–FY2025

+146.1%

+25.25% a year

Each share's claim on the business

−59.4%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $20.1M

over 5 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years6% Under 1 year94%

Quarterly turnover

100.6%

of institutional shares changed hands

Top 10 managers, median time held

2 quarters

Super Investors

Investment managers reporting SPRB on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
AC AIGH Capital Management LLC	250.0K	8.70%	NEW	Q2 '26	0.9%
Shares held by quarter Peak holding250.0K (Q2'26) Change over 8 quarters+250.0K Share of the company8.700% AIGH Capital Management LLC's full portfolio →
OA Orbimed Advisors LLC	200.0K	6.96%	NEW	Q2 '26	0.2%
Shares held by quarter Peak holding200.0K (Q2'26) Change over 8 quarters+200.0K Share of the company6.960% Orbimed Advisors LLC's full portfolio →

AIGH Capital Management LLC

250.0K

% of company

8.70%

Change vs last qtr

NEW

Held since

Q2 '26

Orbimed Advisors LLC

200.0K

% of company

6.96%

Change vs last qtr

NEW

Held since

Q2 '26

27 more super investors behind a free account

See every manager holding Spruce Biosciences, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting SPRB on Form N-PORT; together they hold 10.8% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$4.59M	84.9K	2.96%	0.00%	June 30, 2026
IR iShares Russell 2000 ETF iShares Trust	$3.52M	65.2K	2.27%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$4.59M

% of company

2.96%

% of the fund

0.00%

As of

June 30, 2026

iShares Russell 2000 ETF

iShares Trust

Position value

$3.52M

% of company

2.27%

% of the fund

0.00%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Spruce Biosciences, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
JS Jay Schmelter 5%+ holder 13D · 4.2%	1.8M	61.22%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company61.220% Disclosed stake13D · 4.2% View the 13D/G filing →
JP John P. McKearn, Ph.D. 5%+ holder 13D · 4.2%	1.8M	61.22%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company61.220% Disclosed stake13D · 4.2% View the 13D/G filing →

Jay Schmelter

5%+ holder13D · 4.2%

1.8M

% of company

61.22%

Change vs last qtr

—

Held since

—

John P. McKearn, Ph.D.

5%+ holder13D · 4.2%

1.8M

% of company

61.22%

Change vs last qtr

—

Held since

—

22 more holders behind a free account

See every insider and 5%+ holder of Spruce Biosciences, Inc..

Comments